Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 1 · 25%High 0 · 0%

Methotrexate vs alternative disease‐modifying antirheumatic drugs

Withdrawals due to adverse events · children and young people with JIA

Methotrexate showed no clear difference in withdrawals due to adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).

1 finding from 1 review

Methotrexate for juvenile idiopathic arthritis 2024 · Cochrane Headline outcomes only
RR 0.33 [0.04, 3.09]
1 study · 94 participants
Low

Methotrexate vs placebo

Withdrawals due to adverse events · children and young people with JIA

Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).

1 finding from 1 review

Methotrexate for juvenile idiopathic arthritis 2024 · Cochrane Headline outcomes only
RR 3.46 [0.6, 19.79]
3 studies · 328 participants
Low

Summary of findings: leflunomide + methotrexate vs methotrexate

Withdrawals due to adverse events · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
1 study · 263 participants
Moderate

Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone

Withdrawals due to adverse events · children and young people with JIA

Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in withdrawals due to adverse events(12 months) compared with intra‐articular glucocorticoid alone (low certainty).

1 finding from 1 review

Methotrexate for juvenile idiopathic arthritis 2024 · Cochrane Headline outcomes only
RR 8.75 [0.48, 160.4]
1 study · 207 participants
Low